| Next 10 |
Ad
ALXO News and Press ALX Oncology Holdings Inc.
News | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
-
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 w...
-
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced th...
-
2025-05-08 10:16:33 ET More on ALX Oncology ALX Oncology falls on mid-stage trial setback for lead asset ALX Oncology jumps as Jefferies upgrades on upside potential Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology...
-
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...
-
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patientsȁ...
-
2025-04-25 10:58:07 ET More on ALX Oncology ALX Oncology jumps as Jefferies upgrades on upside potential Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology Financial information for ALX Oncology Read the fu...
-
2025-04-07 09:23:25 ET More on ALX Oncology ALX Oncology jumps as Jefferies upgrades on upside potential ALX Oncology stock falls 16% amid Phase 2 data update Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology ...
-
2025-03-06 17:41:25 ET More on ALX Oncology ALX Oncology jumps as Jefferies upgrades on upside potential ALX Oncology stock falls 16% amid Phase 2 data update Seeking Alpha’s Quant Rating on ALX Oncology Read the full article on Seeking Alpha F...
-
2025-03-06 17:04:07 ET More on ALX Oncology ALX Oncology jumps as Jefferies upgrades on upside potential ALX Oncology stock falls 16% amid Phase 2 data update Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology ...
-
2025-03-06 14:31:58 ET More on ALX Oncology ALX Oncology stock falls 16% amid Phase 2 data update ALX Oncology falls as Jefferies cuts on lead cancer drug Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology Fi...
Stock Information
Get ALXO Alerts
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
-0.26% G/L:
$0.4302 Last:
398,408 Volume:
$0.44 Open:
$0.4313 Close:
ALX Oncology Holdings Inc. Website:
Ad
-
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 w...
-
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced th...
-
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...